Pancreatic Adenocarcinoma Therapeutics Market Size Analysis To 2019
Pancreatic adenocarcinoma is also referred to as pancreatic cancer (PC). It is an illness primarily affecting the elderly populace. Seventy five percent of pancreatic adenocarcinomas are detected in patients aged more than seventy five years. Pancreatic cancer grows fast, is asymptomatic initially, and displays only non-specific symptoms later.
Pancreatic adenocarcinoma is also referred to as pancreatic cancer (PC). It is an illness primarily affecting the elderly populace. Seventy five percent of pancreatic adenocarcinomas are detected in patients aged more than seventy five years. Pancreatic cancer grows fast, is asymptomatic initially, and displays only non-specific symptoms later.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4.3.1 Enhancing Drug Delivery 44<br />
4.3.2 Targeted Therapies 44<br />
4.3.3 Immunotherapy 45<br />
4.4 Clinical Trial Duration and <strong>Size</strong> 47<br />
4.5 Clinical Trial Failure Rate 50<br />
4.6 Clinical Trial Discussion 51<br />
4.7 Promising Drug Candidates in Pipeline 53<br />
4.7.1 Masivet/Kinavet (US) - AB Science 53<br />
4.7.2 Glufosfamide - Eleison Pharmaceuticals Incorporated 54<br />
4.7.3 Tertomotide - Kael-GemVax Co., Ltd 55<br />
4.7.4 TH-302 - Threshold Pharmaceuticals 56<br />
4.7.5 HyperAcute Pancreas - NewLink Genetics Corporation 58<br />
4.7.6 MM-398 - Merrimack Pharmaceuticals Inc. 60<br />
4.8 Pipeline Discussion 62<br />
Request Free Sample Of This Study @<br />
http://www.radiantinsights.com/research/pancreatic-adenocarcinoma-therapeutics-inmajor-developed-markets-to-<strong>2019</strong>-early-stage-pipeline-shows-diversity-of-novel-targetsthough-commercial-impact-remains-distant#tabs-4<br />
5 <strong>Market</strong> Forecast 67<br />
5.1 Introduction 67<br />
5.2 Global <strong>Market</strong> 67<br />
5.3 North America 70<br />
5.3.1 Treatment Usage Patterns 70<br />
5.3.2 Annual Cost of Therapy 71<br />
5.3.3 <strong>Market</strong> <strong>Size</strong> 73<br />
5.4 <strong>To</strong>p Five European Countries 75<br />
5.4.1 Treatment Usage Patterns 75<br />
5.5 Annual Cost of Therapy 77<br />
5.6 <strong>Market</strong> <strong>Size</strong> 79<br />
5.7 Japan 81<br />
5.7.1 Treatment Usage Patterns 81<br />
5.7.2 Annual Cost of Therapy 82<br />
5.7.3 <strong>Market</strong> <strong>Size</strong> 82<br />
5.8 Drivers and Barriers 83<br />
5.8.1 Drivers 83<br />
5.8.2 Barriers 84<br />
6 Deals 87<br />
6.1 Licensing Deals 87<br />
6.1.1 Clavis Enters Licensing and Development Agreement with Clovis 89<br />
6.1.2 Baxter Enters Licensing Agreement with Onconova for Rigosertib 90<br />
6.1.3 Lorus <strong>Therapeutics</strong> Enters Into Licensing Agreement with Zor Pharma 90
Change language